A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers
| Autor: | Paras N. Prasad, Linda J. Krebs, Atilla Nagy, Charles Liebow, Xiaopeng Wang, Andrew V. Schally |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Cancer Research
medicine.medical_specialty Gonadotropin-releasing hormone Biology Gonadotropin-Releasing Hormone Epidermal growth factor Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Tumor Cells Cultured Humans Doxorubicin MTT assay Receptor Laryngeal Neoplasms Mouth neoplasm Epidermal Growth Factor Endocrinology Oncology Epidermoid carcinoma Cancer research Mouth Neoplasms Oral Surgery Drug Screening Assays Antitumor Luteinizing hormone Cell Division medicine.drug |
| Zdroj: | Oral oncology. 38(7) |
| ISSN: | 1368-8375 |
| Popis: | A doxorubicin and [D-Lys(6)]Luteinizing Hormone-Releasing Hormone (LH-RH) conjugate, AN-152, was designed to target LH-RH receptor positive cells. AN-152 is more potent against a specific group of cancers than doxorubicin and has less peripheral toxicity. This therapy is potentially efficacious against many other types of malignancies. Here, AN-152 was tested on oral (KB) and laryngeal (HEp-2) carcinoma cells. LH-RH receptor presence was demonstrated by displacement binding assays. Cells were treated with 10 nM EGF or left untreated, then exposed to 0-10 microM AN-152. Cytotoxicity was assessed by MTT assay to determine ED(50) values. AN-152 association with the cells was monitored using two-photon laser scanning microscopy. AN-152 was more potent than doxorubicin in both KB and HEp-2 cell lines (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect